MX2020006112A - Complejo que comprende un compuesto orientado a psma vinculado a un radionucleido de plomo o torio. - Google Patents

Complejo que comprende un compuesto orientado a psma vinculado a un radionucleido de plomo o torio.

Info

Publication number
MX2020006112A
MX2020006112A MX2020006112A MX2020006112A MX2020006112A MX 2020006112 A MX2020006112 A MX 2020006112A MX 2020006112 A MX2020006112 A MX 2020006112A MX 2020006112 A MX2020006112 A MX 2020006112A MX 2020006112 A MX2020006112 A MX 2020006112A
Authority
MX
Mexico
Prior art keywords
psma
sup
complex
lead
compound linked
Prior art date
Application number
MX2020006112A
Other languages
English (en)
Inventor
Roy Hartvig Larsen
Original Assignee
Sciencons AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciencons AS filed Critical Sciencons AS
Publication of MX2020006112A publication Critical patent/MX2020006112A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/24—Lead compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/003—Compounds containing elements of Groups 2 or 12 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/94—Bismuth compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a complejos que comprenden un compuesto orientado a antígeno de membrana específico de próstata (PSMA) vinculado a un radionucleido, tal como 212Pb o 227Th, a través de una fracción quelante de TCMC o DOTA. Estos compuestos, y las composiciones farmacéuticas que los comprenden, pueden usarse para aplicaciones médicas. Estas aplicaciones incluyen el tratamiento del cáncer de próstata, y los complejos permiten la doble orientación de cánceres.
MX2020006112A 2017-12-13 2018-12-13 Complejo que comprende un compuesto orientado a psma vinculado a un radionucleido de plomo o torio. MX2020006112A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17206887 2017-12-13
PCT/EP2018/084738 WO2019115684A1 (en) 2017-12-13 2018-12-13 Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide

Publications (1)

Publication Number Publication Date
MX2020006112A true MX2020006112A (es) 2020-08-24

Family

ID=60673489

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006112A MX2020006112A (es) 2017-12-13 2018-12-13 Complejo que comprende un compuesto orientado a psma vinculado a un radionucleido de plomo o torio.

Country Status (15)

Country Link
US (3) US10377778B2 (es)
EP (2) EP3723816A1 (es)
JP (2) JP7376481B2 (es)
KR (1) KR20200111169A (es)
CN (2) CN111491668B (es)
AU (1) AU2018382539A1 (es)
BR (1) BR112020011789A2 (es)
CA (1) CA3085205A1 (es)
IL (2) IL295190A (es)
MX (1) MX2020006112A (es)
PH (1) PH12020550898A1 (es)
SG (1) SG11202005511VA (es)
UA (1) UA127532C2 (es)
WO (1) WO2019115684A1 (es)
ZA (1) ZA202003877B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211760A1 (es) 2013-10-18 2021-09-07 Deutsches Krebsforsch Inhibidores marcados de antigeno prostatico especifico de membrana (psma) que comprenden grupos carboxilicos y una region de enlazador modificada, agentes formadores de imagenes y agentes farmaceuticos que los comprenden
AU2019287595A1 (en) * 2018-04-27 2020-12-03 University Of Iowa Research Foundation Compositions for chelating metals at low temperatures
US20220125957A1 (en) * 2018-09-21 2022-04-28 Endocyte, Inc. Methods of treating cancer
EP3856261A1 (en) * 2018-09-28 2021-08-04 Universität Heidelberg Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
JP2023514333A (ja) * 2020-02-18 2023-04-05 エンドサイト・インコーポレイテッド Ｐｓｍａ発現がんを処置する方法
IL297423A (en) * 2020-04-24 2022-12-01 Radiomedix Inc The composition, kit and method for the diagnosis and treatment of prostate cancer
CA3184226A1 (en) * 2020-06-29 2022-01-06 Steven Larson Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy
NL2028075B1 (en) * 2021-04-26 2022-11-03 Alphathera Ag Targeting system for cancer comprising a radioisotope
WO2023030509A1 (zh) * 2021-09-03 2023-03-09 晶核生物医药科技(南京)有限公司 一种肽脲素衍生物、含其的药物组合物及其应用
IT202100024335A1 (it) * 2021-09-22 2023-03-22 Scogif S R L Complesso radiofarmaceutico per l’imaging e/o per la localizzazione di cellule positive al psma
CN114014843B (zh) * 2021-11-17 2022-09-20 北京大学第一医院 一种psma靶向核素/荧光双模态配体和分子探针与应用
WO2023139203A1 (en) * 2022-01-21 2023-07-27 Sciencons AS Complexes for cancer treatment and imaging
US20230264044A1 (en) * 2022-02-24 2023-08-24 Alpha Tau Medical Ltd. Convection-Enhanced Diffusing Alpha-Emitter Radiation Therapy
WO2023240135A2 (en) * 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
WO2024101993A1 (en) 2022-11-09 2024-05-16 Coretag IP B.V. Targeting system for cancer treatment
CN117045828A (zh) * 2023-10-12 2023-11-14 北京先通国际医药科技股份有限公司 212Pb标记的放射性化合物在制备治疗前列腺癌药物中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008105773A2 (en) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
US8926944B2 (en) * 2011-08-05 2015-01-06 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors
PE20211760A1 (es) * 2013-10-18 2021-09-07 Deutsches Krebsforsch Inhibidores marcados de antigeno prostatico especifico de membrana (psma) que comprenden grupos carboxilicos y una region de enlazador modificada, agentes formadores de imagenes y agentes farmaceuticos que los comprenden
EP3140282B1 (en) * 2014-05-06 2019-07-10 The Johns Hopkins University Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
WO2016040179A1 (en) 2014-09-08 2016-03-17 Molecular Insight Pharmaceuticals, Inc. Organ protection in psma-targeted radionuclide therapy of prostate cancer
EP3204018B1 (en) 2014-10-07 2021-08-25 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
US9433690B1 (en) * 2015-02-26 2016-09-06 Sciencons AS Radiopharmaceutical solutions with advantageous properties
IL237525A (en) * 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
WO2017165473A1 (en) * 2016-03-22 2017-09-28 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

Also Published As

Publication number Publication date
CN111491668A (zh) 2020-08-04
RU2020120946A (ru) 2022-01-13
WO2019115684A1 (en) 2019-06-20
AU2018382539A1 (en) 2020-07-02
EP3723816A1 (en) 2020-10-21
BR112020011789A2 (pt) 2020-11-24
EP3498308A1 (en) 2019-06-19
IL295190A (en) 2022-09-01
US20190177345A1 (en) 2019-06-13
PH12020550898A1 (en) 2021-03-22
US20240182501A1 (en) 2024-06-06
KR20200111169A (ko) 2020-09-28
JP7376481B2 (ja) 2023-11-08
CN116023429A (zh) 2023-04-28
JP2021506784A (ja) 2021-02-22
US10377778B2 (en) 2019-08-13
CA3085205A1 (en) 2019-06-20
UA127532C2 (uk) 2023-09-27
IL275317B (en) 2022-09-01
JP2023178476A (ja) 2023-12-14
CN111491668B (zh) 2023-01-24
US20200297877A1 (en) 2020-09-24
IL275317A (en) 2020-07-30
SG11202005511VA (en) 2020-07-29
ZA202003877B (en) 2021-07-28

Similar Documents

Publication Publication Date Title
MX2020006112A (es) Complejo que comprende un compuesto orientado a psma vinculado a un radionucleido de plomo o torio.
WO2018140831A3 (en) Tumor targeting conjugates and methods of use thereof
GEP20237479B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
MX2022014611A (es) Compuestos para tomografia por emision de positrones.
ZA201906832B (en) Novel psma-binding agents and uses thereof
PH12019500214A1 (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
MX343405B (es) Complejos que emiten alfa-particulas objetivo que comprenden radionuclido de torio e hidroxipiridinona que contiene ligando.
MX2016015176A (es) Conjugacion especifica de sitio de farmacos enlazadores con anticuerpos y conjugados farmaco-anticuerpo (adc) resultantes.
MX2017003886A (es) Conjugado radiofarmaceutico de un metabolito y un agente epr para tratar celulas tumorales.
MX2016007851A (es) Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos.
MX2016007826A (es) Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco.
NZ739770A (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
MX2021013055A (es) Inhibidores de antigenos de membrana especificos de prostata (psma) como agentes diagnosticos y terapeuticos con radionuclidos.
MX2018000239A (es) Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.
MX2023005053A (es) Ligandos de psma para la formacion de imagenes y endorradioterapia.
MX2019004963A (es) Conjugados y particulas especificos del sstr y formulaciones de los mismos.
JOP20220070A1 (ar) مترافقات جسم مضاد- عقار مضاد لميزوثيلين إيريبولين وطرق استخدامها
MX2021012769A (es) Anticuerpos bloqueadores cd73.
PH12020551471A1 (en) Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer
MX2022011635A (es) Radioinmunoconjugados dirigidos a fgfr3 y usos de estos.
MX2022000136A (es) Ligandos del antigeno de membrana especifico de la prostata (psma) y usos de los mismos.
MX2021003295A (es) Enlazadores basados en sulfomaleimida y sus correspondientes conjugados.
EA202090575A2 (ru) Соединения для позитронно-эмиссионной томографии
MX2019013019A (es) USO DE 3,16-DIACETADO DE 26-AZIDO-22-OXOCOLEST-5-3ß, 16ß-DIILO COMO AGENTE ANTICANCERIGENO.
NZ758917A (en) Compounds for positron emission tomography